{"id":11315,"date":"2020-05-15T13:17:56","date_gmt":"2020-05-15T12:17:56","guid":{"rendered":"https:\/\/montpellier-cancer.com\/?page_id=11315"},"modified":"2023-11-23T17:54:43","modified_gmt":"2023-11-23T16:54:43","slug":"screening-platform-in-oncology-pcc","status":"publish","type":"page","link":"https:\/\/montpellier-cancer.com\/en\/recherche\/plateformes-en-cancerologie\/screening-platform-in-oncology-pcc\/","title":{"rendered":"Screening Platform in Oncology – PCC"},"content":{"rendered":"
\n
\n
\n

The screening platform in Oncology develops and uses cellular models in order to characterize the affinity and activity of pharmaceutical, natural or environmental ligands of nuclear receptors involved in carcinogenesis (estrogen and androgen receptors, pregnane X receptors) as well as the antiproliferative activity of molecules with an anticancer vocation (antiestrogens, antiandrogens, aromatase and hsp inhibitors, cytotoxins, antibodies, thymidine kinase inhibitors).<\/p>\n

Its services also include the establishment of cell lines expressing luciferase constitutively or under the control of a transcription factor (nuclear receptor, dioxin receptor, AP1 factor, etc.) or expressing a protein of interest (enzyme, receptor, etc.).<\/p>\n<\/div>\n <\/div>\n <\/div>\n <\/div>\n\n\n

\n
\n
\n
\n

Contact<\/h2>\n <\/div>\n
\n
\n
\n \n <\/div>\n\n